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BRIEF COMMUNICATION
Autosomal recessive cardiomyopathy and sudden cardiac
death associated with variants in MYL3
Daniel Peter Sayer Osborn, PhD1,11, Leila Emrahi, MSc2,11, Joshua Clayton, PhD3, Mehrnoush Toufan Tabrizi, MD4,
Alex Yui Bong Wan, PhD1, Reza Maroofian, PhD1, Mohammad Yazdchi, MD5, Michael Leon Enrique Garcia, BSc1, Hamid Galehdari, PhD6,
Camila Hesse, PhD7, Gholamreza Shariati, MD, PhD8, Neda Mazaheri, MSc6, Alireza Sedaghat, MD9, Hayley Goullée, BMedSci3,
Nigel Laing, PhD3, Yalda Jamshidi, PhD1,12✉ and Homa Tajsharghi, PhD 3,10,12✉
PURPOSE: Variants in genes encoding sarcomeric proteins are the most common cause of inherited cardiomyopathies. However,
the underlying genetic cause remains unknown in many cases. We used exome sequencing to reveal the genetic etiology in
patients with recessive familial cardiomyopathy.
METHODS: Exome sequencing was carried out in three consanguineous families. Functional assessment of the variants was
performed.
RESULTS: Affected individuals presented with hypertrophic or dilated cardiomyopathy of variable severity from infantile- to early
adulthood–onset and sudden cardiac death. We identified a homozygous missense substitution (c.170C>A, p.[Ala57Asp]), a
homozygous translation stop codon variant (c.106G>T, p.[Glu36Ter]), and a presumable homozygous essential splice acceptor
variant (c.482-1G>A, predicted to result in skipping of exon 5). Morpholino knockdown of the MYL3 orthologue in zebrafish, cmlc1,
resulted in compromised cardiac function, which could not be rescued by reintroduction of MYL3 carrying either the nonsense
c.106G>T or the missense c.170C>A variants. Minigene assay of the c.482-1G>A variant indicated a splicing defect likely resulting in
disruption of the EF-hand Ca2+ binding domains.
CONCLUSIONS: Our data demonstrate that homozygous MYL3 loss-of-function variants can cause of recessive cardiomyopathy and
occurrence of sudden cardiac death, most likely due to impaired or loss of myosin essential light chain function.
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INTRODUCTION
Hypertrophic cardiomyopathy (HCM) is considered as the leading
cause of sudden cardiac death (SCD) among athletes and young
adults under the age of 30.1 Dilated cardiomyopathy (DCM)
accounts for 30–40% of all heart failure cases and is the
leading indication for heart transplantation.2 Variants in genes
encoding major components of the sarcomere, the basic
contractile unit of striated muscles, are the most common cause
of HCM and DCM, which is mostly transmitted in an autosomal
dominant fashion.
Autosomal dominant and recessive variants in MYL3, which
encodes the ventricular myosin essential light chain (ELC), are a
rare cause of HCM with inter- and intrafamilial variability ranging
from benign to malignant forms with cardiac failure and SCD.3–7 It
has also been suggested that MYL3 variants can result in variable
morphological phenotypes.7–9 There are, however, no reports of
DCM associated with MYL3 variants or cardiomyopathy associated
with likely ELC deficiency due to nonsense or essential splice
acceptor variants in MYL3.
Here, we describe homozygous MYL3 variants, including likely
loss-of-function (LOF) variants, in three unrelated families with
recessive HCM or DCM and occurrence of SCD. Pathogenicity of
the identified variants is supported by functional assessment of
the mutant ELC in zebrafish.
MATERIALS AND METHODS
Patients and genetic analysis
Three unrelated families of Iranian origin were included in this study.
Exome sequencing was performed on patient III.7 and individuals III.1 and
IV.3 from family A, the proband IV.2 from family B, and individual V.2 from
family C, independently. Detailed methods are provided in the Supple-
mentary information. MYL3 transcript NM_000258.2 was used for variant
nomenclature.
RESULTS
Clinical characteristics of the patients
Case reports and full descriptions are provided in the Supplemen-
tary information. All patients were born to consanguineous
parents, either first or second cousins (Fig. 1) presenting with
HCM, DCM, or unclassified cardiomyopathy.
Case III.7, a 38-year-old female from family A, was diagnosed
with HCM at the age of 26 following dyspnea. Family history was
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positive for HCM and occurrence of SCD in four family members
(Fig. 1a). Case IV.2 is an 8-year-old male from family B (Fig. 1b),
who was diagnosed with DCM at the age of 6. He underwent
heart transplantation soon after diagnosis. The only other
clinical feature noted was horseshoe kidney. The affected
brother (IV.1) died at the age of 2 of SCD and renal failure.
Case VI.1, from family C, was a female of apparently healthy
second cousin parents. She was diagnosed with unclassified
cardiomyopathy at the age of 2.5 years and died at the age of 8
years of SCD. Family history was positive for cardiac disease and
occurrence of SCD in three family members (V.5, V.6, and V.8),
who had been diagnosed with unclassified cardiomyopathy
between the ages of 2 and 3 and had died between 5 and 9
years of age (Fig. 1c). There was no record of cardiac evaluation
available for these individuals. The 40-year-old mother (V.2) was
offered genetic testing following the death of her daughter
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Fig. 1 Pedigree of families withMYL3 variants. a–c Pedigrees of families A, B, and C. In the pedigree, squares represent males, circles females,
black shaded symbols denote cardiomyopathy, open symbols represent clinically asymptomatic individuals, and slash indicates deceased.
Family members who were analyzed by next-generation sequencing (arrows) are indicated. Plus (+) and minus (−) signs indicate presence or
absence of the MYL3 variants ([+/+] homozygote, [+/−] heterozygote and [−/−] wild-type). d Multiple sequence alignment confirms that the
p.(Ala57Asp) substitution affects an evolutionarily conserved residue. e Mutated residues and myosin ELC protein structure: previously
identified missense variants with clinical support associated with familial hypertrophic cardiomyopathy (HCM) (black arrows), nearly all located
at EF-hand motifs of myosin ELC, and the currently identified variants, p.(Ala57Asp), p.(Glu36Ter) and the splice acceptor variant, c.482-1G>A
(red arrows). The actin- and Ca2+-binding sites, proline-rich regions and EF-hand motifs of the myosin ELC are indicated.
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(VI.1). Unfortunately, there was no tissue available from the
deceased individual VI.1.
Affected individuals from the three families showed no
evidence of muscle weakness by neurological examination or by
history.
Genetic findings
Familial genotyping results and MYL3 variant details are summar-
ized in Fig. 1 and Fig. S2. After filtering of exome sequencing data,
no rare, likely pathogenic heterozygous, or homozygous variants
in other cardiomyopathy-associated genes were identified. In all
families, bidirectional Sanger sequencing analysis validated the
identified MYL3 variants confirming a recessive mode of
inheritance associated with the cardiomyopathy in families A
and B, and in keeping with the consanguineous family history,
likely recessive inheritance in family C.
In family A, a homozygous missense variant, c.170C>A
(rs139794067), was identified. It leads to substitution of an
evolutionarily highly conserved residue (p.[Ala57Asp]) within the
EF-hand Ca2+ binding motif of ELC (Fig. 1d, e). In family B, a novel
homozygous c.106G>T variant that introduces a premature
termination codon at position 36 (p.[Glu36Ter]) was identified
(Fig. 1b and S2B). The mother of the proband in family C was
found to harbor a heterozygous c.482-1G>A (rs727503300) variant
predicted to abolish the acceptor splice-site of MYL3 exon 5 by in
silico splicing programs, likely leading to an abnormal or absent
protein (Fig. 1c and S2C). Sanger sequencing confirmed the
appearance of the c.482-1G>A variant in the father of the proband
(Fig. 1c and S2C), suggesting the likelihood of homozygosity of the
variant in the deceased proband. The c.170C>A variant was
present on one allele in the Genome Aggregation Database
(gnomAD) (frequency 0.01588%). The c.106G>T and c.482-1G>A
variants were not present in gnomAD or The Greater Middle East
(GME) Variome Project. The c.482-1G>A variant was present in the
heterozygous state in one individual of our in-house database of
1095 exomes. None of these variants were identified in the
homozygous state in any database. The three MYL3 substitutions
are suggested to be disease causing by in silico predictors
(MutationTaster, PolyPhen-2 [probably damaging], SIFT [deleter-
ious], and PMut [pathogenic]). Based on the American College of
Medical Genetics and Genomics (ACMG) criteria,10 the
pathogenicity of the MYL3 c.170C>A, c.106G>T, and c.482-1G>A
variants were scored as variant of uncertain significance (VUS),
pathogenic, and likely pathogenic, respectively (Table S2).
MYL3 variants are unable to rescue zebrafish loss of cmlc1 function
To investigate the functional consequences of the identified
variants, we turned to the zebrafish as a model organism. Two
cardiac specific myosin light chain orthologs exist in zebrafish,
cmlc1 and cmlc2.11 Cmlc1 shows over 70% homology with human
ELC, and is highly expressed in zebrafish ventricle and weakly
expressed in the atrium, while cmlc2 is homologous to human
myosin regulatory light chain (RLC).11 We examined the knock-
down phenotype of cmlc1, using a previously characterized
morpholino.11 In agreement with published data, we observed
cardiac specific defects in cmlc1 morphant embryos (Fig. 2a, b).
Compared with the control (Movies S1 and S9), morphants
displayed a nonfunctioning heart, characterized by a small
ventricle with reduced contractility and a dilated atrium (n=
116/120, p < 0.01, Fig. 2 & Movie S2). Circulating blood is absent to
slow in morphants, and ventricular regurgitation is apparent
(Movies S2 and S10). To examine conservation of function
between human MYL3 and zebrafish cmlc1, RNA for human
MYL3 was coinjected with control or cmlc1 morpholino into one-
cell staged embryos. Overexpression of MYL3 transcript had no
discernible effect on cardiac function in control-injected mor-
phants (Fig.2 and Movie S3). Overexpression of MYL3 RNA in cmlc1
morphants led to a significant improvement in cardiac function,
with a notable rescue of heart function (n= 11/29, p < 0.01,
Fig. 2c) and significant improvement of ventricular contractions,
quantified by measuring the percentage-shortening fraction
between diastolic and systolic states (MO:x7.3, MO+MYL3:
x17.7, P ≤ 0.001, Fig. 2d and Movies S4 and S11). Thus, MYL3
shows conserved function to cmlc1 in the zebrafish and represents
a valid system for testing pathogenic function of MYL3 variants.
To evaluate the functional consequences of the MYL3 variants
identified in the patients, we performed rescue experiments using
RNAs encoding the missense variant c.170C>A and nonsense
variant c.106G>T, both of which convert highly conserved codons
in human ELC and in the corresponding zebrafish cmlc1 (Fig. 2a
and Movies S5–S8, S12 and S13). Coinjection of c.170C>A RNA
with cmlc1 morpholino only partially rescued the morphant
Fig. 2 MYL3 zebrafish modeling and minigene assay MYL3 zebrafish modeling. Knockdown of the zebrafish homolog of MYL3, cmlc1 causes
ventricular constriction and atrial dilation that can be rescued by wild-type MYL3 but not mutant RNA harboring the patient variants c.170C>A
and c.106G>T. RNA alone or plus morpholino were injected into the cytoplasm of one-cell staged embryos and allowed to develop to 48 hpf.
a cmlc1 morphant embryos showed an enlarged atrium (arrow) compared with control (con) morpholino injected embryos. The cmlc1
morphant phenotype was partially rescued by coinjection of c.170C>A RNA; embryos still showed a dilated atrium (arrow), however, displayed
some improvement in heart function (categorized by observed blood flow). RNA carrying the c.106G>T variant failed to rescue the cmlc1
morphant phenotype. Scale bar: 200 μm. b Fluorescent antibody stain for atrial specific MYH6 (S46, green) and ventricular enriched MYH1
(MF20, red) at 48 hpf. Note the ventricular rescue in MYL3 coinjected morphants compared with the morpholino injected embryos alone
(arrow heads). Scale bar: 10 μm. c Qualitative analysis of cardiac function in embryos injected with either control or cmlc1 morpholino alone,
RNA encoding MYL3, MYL3 170C>A, or MYL3 106G>T RNA alone, or coinjected with morpholino and RNA. The heart was considered functional
(FH) if both chambers contracted and blood flow was observed. d Quantitative analysis of the ventricular shortening fraction (the percentage
area difference between diastolic and systolic state) shows significant improvement of contractility in morphants injected with human MYL3
compared with those injected with variants c.170C>A or c.106G>T (con: x 35.7±SEM 1.4 n= 10, MO: x7.3±SEM 0.8 n= 10, MO+MYL3: x17.7 ±
SEM2.3 n= 7, MO+ 170C>A: x 9.0±SEM 1.1 n= 9, MO+ 106G>T: x 6.5 ± SEM0.9 n= 9. ***P ≤ 0.001, ns: not significant). Minigene assay of the
MYL3 c.482-1G>A variant. The MYL3 c.482-1G>A variant results in exon 5 skipping or removal of the first nucleotide of exon 5. e Agarose gel
of reverse transcription polymerase chain reaction (RT-PCR) products from a minigene assay for the MYL3 c.482-1G>A variant. The wild-type
(WT) expression construct produced only products of the expected size (~300 bp), indicative of correct splicing of MYL3 exon 5. Both mutant
(MUT) expression clones (generated by site-directed mutagenesis) contain a band around the expected size (~300 bp) and a dominant,
smaller band (~220 bp). f Relative abundance of RT-PCR products in each lane calculated by densitometry. g Consensus splice acceptor
sequences,19 MYL3 intron 4/exon 5 wild-type and mutant splice acceptor sequences. The variant (red; A) generates a new consensus splice
sequence (AG, underlined) shifted one nucleotide compared with wild-type (blue; G). h The ~300-bp RT-PCR product contains a single-
nucleotide deletion (G) at the start of MYL3 exon 5 (*), confirming the use of the newly generated splice acceptor sequence. The ~200 bp RT-
PCR product shows complete skipping of exon 5. Based on densitometry (f), exon 5 skipping represents the more frequent event. i Amino acid
alignment of wild-type myosin ELC protein sequence (Uniprot P08590), and proteins generated with exon 5 deletion (ex5_DEL) or one
nucleotide deletion (1nt_DEL). Mismatches and deletions are indicated in red. Both splicing consequences would impact the EF-hand domain
2 (AA 128–163, purple) and EF-hand domain 3 (AA 163–195, green).
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phenotype, and embryos still presented with a dilated atrium
despite some improvement in cardiac function as observed by
more efficient blood circulation, compared with cmlc1 morphants
alone (n= 12/26, p < 0.01, Fig. 2a, c and Movies S6 and S12).
However, a closer examination of the percentage-shortening
fraction showed, despite a slight increase in absolute value, no
significant improvement in ventricular contractility (MO: x7.3,
MO+ 170C>A: x 9.0, Fig. 2d). Coinjections of c.170C>A RNA with
control morpholino had no effect on heart function (n= 35/36,
Fig. 2a, c and Movie S5). The nonsense-coding variant c.106G>T,
predicted to activate nonsense-mediated decay of the MYL3
transcript, or if translated to form a nonfunctional truncated
protein (159-aa C-terminal deletion), was unable to rescue the
cmlc1 morphant phenotype (n= 58/58, Fig. 2a,c, and Movies S7
and S13). Indeed, analysis of ventricular percentage-shortening
fraction showed no significant difference in morphants injected
with c.106G>T RNA compared with morphants alone (MO: x7.3,
MO+ 106G>T: x 6.5, Fig. 2d). Injection of the c.106G>T RNA in
combination with the control morpholino had no effect on
zebrafish heart development or function (n= 53/53, Fig. 2a, c and
Movie S8). Taken together, these data suggest that both MYL3
variants (p.[Ala57Asp] and p.[Glu36Ter]) are highly likely to be
disease causing.
MYL3 c.482-1G>A variant leads to the disruption of EF-hand Ca2+
binding motifs of the myosin ELC
The predominant consequence of the MYL3 c.482-1G>A variant, as
assessed using a minigene assay, is skipping of exon 5, which
results in a protein change (p.[Gly161_Glu186del]), thereby
disrupting the EF-hand Ca2+ binding motifs 2 and 3 (Fig. 2e, f,
h, i). The less frequent consequence of this variant is deletion of
the first nucleotide of exon 5, causing a frameshift p.(Gly161-
Valfs*4) (as per Human Genome Variation Society Guidelines
[HGVS] guidelines) (Fig. 2g). This would completely abolish the EF-
hand 3 domain and disrupt the last 3 AA of the EF-hand 2 domain
(Fig. 2i). Detailed results are provided in the Supplementary
information.
DISCUSSION
Variants in MYL3 are rarely involved in familial cardiomyopathy,4–7
and recessive LOF MYL3 variants, thus far, have not been
described. The majority of reported variants are, however,
associated with SCD at a young age.3,5
Here, we identify recessive variants in MYL3 in three unrelated
families presenting with hypertrophic, dilated, or unclassified
cardiomyopathy of variable severity from infantile- to early
adulthood–onset and SCD. Homozygosity for LOF variants, p.
(Glu36Ter) in family B, and likely homozygosity of the splice
acceptor variant, c.482-1G>A in family C, appear to cause a more
severe phenotype resulting in early SCD and fatality. In addition,
we describe a missense variant, p.(Ala57Asp), in a large family with
recessive HCM and occurrence of SCD. Lack of clinical features in
heterozygous individuals in the families supports the association
of cardiomyopathy with homozygosity for the variants. Although
the presence of the variants could not be confirmed in family
members who died of SCD, homozygosity for the variants is likely
due to the consanguinity.
The p.(Ala57Asp) affects a highly conserved amino acid residue
in the EF-hand Ca2+ binding motifs near the interface of the
myosin heavy and light chains5,7 (Fig. 1d, e). The EF-hand motifs
function as calcium sensors, undergoing a conformational change
upon binding of calcium that is critical for proper muscle
contraction, force production and cardiac function.7 A number
of HCM-associated variants, including p.(Glu56Gly) and p.
(Ala57Gly), are located in the EF-hand Ca2+ binding motifs5,7
(Fig. 1c). No clinical information is available for the p.(Glu56Gly)
variant12 but the p.(Ala57Gly) variant has been reported in two
unrelated Korean families and one Japanese patient with
dominant familial asymmetric septal hypertrophy and a high
incidence of SCD.13 Although heterozygosity for the p.(Ala57Asp)
variant has been reported in some cohorts, no clear clinical
information or family history of the patients was described to
provide support for this variant being pathogenic in the
heterozygous state.14–16 Homozygosity for the p.(Ala57Asp) has
been reported in a single patient with HCM and autosomal
recessive mode of inheritance was suggested due to the lack of
clinical manifestations in the mother of the proband.17 While
induced pluripotent stem cell (iPSC)–derived cardiomyocytes from
an asymptomatic individual who was heterozygous for this variant
did not show an HCM phenotype,18 this may also reflect the
genetic background of the heterozygote and the presence of
gene modifiers in this individual.
Our zebrafish data provide support for pathogenicity of the
variants tested. Expression of c.106G>T MYL3 or c.170C>A MYL3 in
cmlc1 morphants was unable to rescue the characteristic cardiac
phenotype, in contrast to wild-type MYL3, which generated
embryos with functional ventricles and significant blood flow.
This suggests that (1) ELC function is conserved in zebrafish and
(2) since the morphant phenotype can be rescued, the
morpholino effect is specific to cmlc1, and not a result of potential
off-target effects associated with morpholino use. We acknowl-
edge that a proportion of morphant embryos injected with wild-
type messenger RNA (mRNA) failed to rescue the heart phenotype;
we speculate that this might be due to several limitations imposed
by the method. Indeed, microinjection of capped mRNA into the
one-cell stage embryo leads to transient expression of gene
products that usually degrade by 72 hpf. It is feasible that for some
embryos the mRNA has degraded before it has completed its
expression effect. In addition, it is likely that uptake of mRNA into
the cell is heterogeneous and mosaic. Thus cells destined to a
cardiac fate may not always receive the amount necessary for
rescue, and this may vary between injected embryos. Another
limitation for a technique that relies on injections of coding RNA is
the incompatibility for testing the consequences of splicing
variants such as c.482-1G>A. However, conducting a minigene
assay revealed that the c.482-1G>A splicing variant resulted in a
predominant complete deletion of exon 5 of the transcript leading
to disruption of the highly conserved EF-hand Ca2+ binding motifs
of the myosin ELC.
In conclusion, we identify homozygous variants in MYL3 in three
unrelated families with cardiomyopathies and occurrence of SCD,
but no skeletal myopathy. The recessive inheritance of the likely
LOF MYL3 variants are associated with a particularly severe
phenotype resulting in early SCD and lethality. Furthermore, our
in vivo zebrafish data provide support for the causality of the
nonsense variant c.106G>T and missense variant c.170C>A, and
that perturbations in myosin ELC function lead to cardiac specific
defects.
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